Deeptrasynergy: Drug Combinations Using Multimodal Deep Learning With Transformers Publisher Pubmed



Rafiei F¹ ; Zeraati H¹ ; Abbasi K² ; Ghasemi JB³ ; Parsaeian M^{1, 4} ; Masoudinejad A⁵ Show Affiliations
Source: Bioinformatics Published:2023

Abstract

Motivation: Screening bioactive compounds in cancer cell lines receive more attention. Multidisciplinary drugs or drug combinations have a more effective role in treatments and selectively inhibit the growth of cancer cells. Results: Hence, we propose a new deep learning-based approach for drug combination synergy prediction called DeepTraSynergy. Our proposed approach utilizes multimodal input including drug–target interaction, protein–protein interaction, and cell–target interaction to predict drug combination synergy. To learn the feature representation of drugs, we have utilized transformers. It is worth noting that our approach is a multitask approach that predicts three outputs including the drug–target interaction, its toxic effect, and drug combination synergy. In our approach, drug combination synergy is the main task and the two other ones are the auxiliary tasks that help the approach to learn a better model. In the proposed approach three loss functions are defined: synergy loss, toxic loss, and drug–protein interaction loss. The last two loss functions are designed as auxiliary losses to help learn a better solution. DeepTraSynergy outperforms the classic and state-of-the-art models in predicting synergistic drug combinations on the two latest drug combination datasets. The DeepTraSynergy algorithm achieves accuracy values of 0.7715 and 0.8052 (an improvement over other approaches) on the DrugCombDB and OncologyScreen datasets, respectively. Also, we evaluate the contribution of each component of DeepTraSynergy to show its effectiveness in the proposed method. The introduction of the relation between proteins (PPI networks) and drug–protein interaction significantly improves the prediction of synergistic drug combinations. © 2023 Oxford University Press. All rights reserved.